Mogamulizumab, an anti-CCR4 antibody, targets human T-lymphotropic virus type 1-infected CD8+ and CD4+ T cells to treat associated myelopathy.
Yamauchi J, Coler-Reilly A, Sato T, Araya N, Yagishita N, Ando H, Kunitomo Y, Takahashi K, Tanaka Y, Shibagaki Y, Nishioka K, Nakajima T, Hasegawa Y, Utsunomiya A, Kimura K, Yamano Y.
Yamauchi J, et al. Among authors: shibagaki y.
J Infect Dis. 2015 Jan 15;211(2):238-48. doi: 10.1093/infdis/jiu438. Epub 2014 Aug 7.
J Infect Dis. 2015.
PMID: 25104771